Bronchial asthma and nasal allergy

1938 ◽  
Vol 10 (1) ◽  
pp. 103
Keyword(s):  
Bronchial Asthma ◽  
Nasal Allergy

scholarly journals Nasal Allergy and Bronchial Asthma

1976 ◽  
Vol 27 (1) ◽  
pp. 54-59 ◽  
Author(s):  
Minoru Okuda
Keyword(s):  
Bronchial Asthma ◽  
Nasal Allergy

scholarly journals Effect of Intranasal Beclomethasone Dipropionate Aerosol in the Treatment of Bronchial Asthma Complicated with Nasal Allergy

1980 ◽  
Vol 31 (1) ◽  
pp. 51-64
Author(s):  
Shotaro Mitsui ◽  
Morio Sudo ◽  
Yasuo Kawakami ◽  
Hiroaki Nakajima ◽  
Takatsugu Mue ◽  
...  
Keyword(s):  
Bronchial Asthma ◽  
Beclomethasone Dipropionate ◽  
Nasal Allergy

Clinico-pathological correlation between allergic rhinitis and bronchial asthma

2000 ◽  
Vol 114 (5) ◽  
pp. 354-358 ◽  
Author(s):  
Bipin T. Varghese ◽  
P. S. N. Murthy ◽  
Ranjit Rajan
Keyword(s):  
Allergic Rhinitis ◽  
Prospective Study ◽  
Bronchial Asthma ◽  
Nasal Allergy ◽  
Pathological Findings ◽  
Therapeutic Benefits ◽  
Nasal Symptoms ◽  
Pathological Correlation ◽  
A Prospective Study ◽  
Prompt Attention

A prospective study was carried out on 52 patients with allergic rhinitis, during March 1993–January 1995. This was to analyse the occurrence of bronchial asthma among them and to correlate the symptoms, signs and pathological findings of allergic rhinitis with that of bronchial asthma in those patients with both the disorders. The therapeutic benefits with regard to the symptoms of bronchial asthma in these patients were assessed after treatment of their nasal allergy for a period of at least four months.A definite aetio-clinico-pathological correlation could be established between allergic rhinitis and bronchial asthma and it could be concluded from the study that prompt attention to nasal symptoms in cases with co-existent bronchial asthma helps to a large extent in curbing the symptoms of the latter.

Pathogenesis of Bronchial Asthma

1950 ◽  
Vol 34 (6) ◽  
pp. 1829-1838 ◽  
Author(s):  
John J. Curry
Keyword(s):  
Bronchial Asthma

Atopic dermatitis: new horizons of therapy

2019 ◽  
Vol 1 (7) ◽  
pp. 29-32 ◽  
Author(s):  
L. S. Kruglova ◽  
E. M. Gensler
Keyword(s):  
Blood Pressure ◽  
Immune Response ◽  
Allergic Rhinitis ◽  
Atopic Dermatitis ◽  
Targeted Therapy ◽  
Inflammatory Response ◽  
Bronchial Asthma ◽  
New Horizons ◽  
The Past

Over the past decades, the first breakthrough milestone in the treatment of severe forms of atopic dermatitis (AD) has been targeted therapy aimed at inhibiting IL-4 and IL-13. This was made possible thanks to advances in the understanding of the pathogenesis of AD, the driver of which is the Th2-type immune response, which also underlies such manifestations of atopy as bronchial asthma, allergic rhinitis, and polynosis. In the case of the Th2-type immune response, cytokines IL-4 and IL-13 are secreted, which are the main promoters of the inflammatory response in AD. Inhibition of IL-4 and IL-13 leads to the prevention of inflammation and is an effective approach to therapy. The use of therapy aimed at inhibition of cytokines allows you to effectively cope with the manifestations of severe and moderately severe blood pressure.

Sign in / Sign up

Export Citation Format

Share Document